EJNMMI Research · 2023 · 17 citations · 46 references
MedicineNuclear MedicineRadiologyRadiation DosimetryRadionuclide TherapyTreatment PlanningAbsorbed DosePatient-specific DosimetryRadiation Dose MeasurementRadiation TherapyRadiation Treatment PlanningTreatment Planning Dose CalculationDose Distribution MetricsDose Volume HistogramDose-volume Histogram AnalysisDose-volume RelationshipRadiation Dose AssessmentSelective Internal Radiation TherapyTreatment Planning DosimetryVoxel Dosimetry
Abstract Background Selective internal radiation therapy with 90 Y radioembolization aims to selectively irradiate liver tumours by administering radioactive microspheres under the theragnostic assumption that the pre-therapy injection of 99m Tc labelled macroaggregated albumin ( 99m Tc-MAA) provides an estimation of the 90 Y microspheres biodistribution, which is not always the case. Due to the growing interest in theragnostic dosimetry for personalized radionuclide therapy, a robust relationship between the delivered and pre-treatment radiation absorbed doses is required. In this work, we aim to investigate the predictive value of absorbed dose metrics calculated from 99m Tc-MAA (simulation) compared to those obtained from 90 Y post-therapy SPECT/CT. Results A total of 79 patients were analysed. Pre- and post-therapy 3D-voxel dosimetry was calculated on 99m Tc-MAA and 90 Y SPECT/CT, respectively, based on Local Deposition Method. Mean absorbed dose, tumour-to-normal ratio, and absorbed dose distribution in terms of dose-volume histogram (DVH) metrics were obtained and compared for each volume of interest (VOI). Mann–Whitney U-test and Pearson’s correlation coefficient were used to assess the correlation between both methods. The effect of the tumoral liver volume on the absorbed dose metrics was also investigated. Strong correlation was found between simulation and therapy mean absorbed doses for all VOIs, although simulation tended to overestimate tumour absorbed doses by 26%. DVH metrics showed good correlation too, but significant differences were found for several metrics, mostly on non-tumoral liver. It was observed that the tumoral liver volume does not significantly affect the differences between simulation and therapy absorbed dose metrics. Conclusion This study supports the strong correlation between absorbed dose metrics from simulation and therapy dosimetry based on 90 Y SPECT/CT, highlighting the predictive ability of 99m Tc-MAA, not only in terms of mean absorbed dose but also of the dose distribution.
46
Étienne Garin, Lambros Tselikas, Boris Guiu et al. · The Lancet. Gastroenterology & hepatology · 2020 · 604 citations
Global, regional and national burden of primary liver cancer by subtype
Harriet Rumgay, Jacques Ferlay, Catherine de Martel et al. · European Journal of Cancer · 2021 · 567 citations
Étienne Garin, Laurence Lenoir, Yan Rolland et al. · Journal of Nuclear Medicine · 2012 · 276 citations · Full text
Medicine, Nuclear Medicine, Oncology +13
William A. Dezarn, Jeffery T. Cessna, Larry A. DeWerd et al. · Medical Physics · 2011 · 260 citations